Free shipping on all orders $250CAD or more within Canada.

Retatrutide

  • HOME
  • |
  • Retatrutide

Retatrutide

SKU RT152605B/RT302605D/RT502605E

Retatrutide is a synthetic 39-amino-acid lipidated peptide designed as a single-molecule agonist of the GIP, GLP-1 and glucagon receptors. Researchers study it in laboratory, preclinical and clinical settings for its effects on metabolic signalling, energy balance, glucose regulation, lipid metabolism and body-weight regulation.

Research includes receptor studies, animal models and controlled human clinical trials examining how simultaneous activation of three metabolically important receptor systems may influence appetite, nutrient handling, energy expenditure and body composition. Retatrutide remains an investigational compound, and its long-term safety and therapeutic role continue to be evaluated in clinical research.

This material is intended for laboratory research only, is not authorized by Health Canada for human therapeutic use, and is not intended for human or veterinary administration.


CA$94.99

In Stock

Choose a kit option to save more, or skip this and buy individually above.

Save 5%
2 Vials x 15mg
CA$180.00 CA$190.00
Save 11%
4 Vials x 15mg
CA$320.00 CA$360.00
Save 19%
6 Vials x 15mg
CA$460.00 CA$570.00
Save 28%
10 Vials x 15mg
CA$680.00 CA$950.00
Save 8%
2 Vials x 30mg
CA$305.00 CA$330.00
Save 11%
4 Vials x 30mg
CA$585.00 CA$660.00
Save 20%
6 Vials x 30mg
CA$790.00 CA$990.00
Save 29%
10 Vials x 30mg
CA$1,170.00 CA$1,650.00
Save 8%
2 Vials x 50mg
CA$405.00 CA$440.00
Save 12%
4 Vials x 50mg
CA$775.00 CA$880.00
Save 20%
6 Vials x 50mg
CA$1,055.00 CA$1,320.00
Save 30%
10 Vials x 50mg
CA$1,540.00 CA$2,200.00
Save 8%
2 Vials x 20mg
CA$230.00 CA$250.00
Save 12%
4 Vials x 20mg
CA$440.00 CA$500.00
Save 20%
6 Vials x 20mg
CA$600.00 CA$750.00
Save 30%
10 Vials x 20mg
CA$875.00 CA$1,250.00
HPLC Purity Verified
Batch Documented
LC-MS Confirmation Available
2°C Storage

*LC-MS identity confirmation may be performed when analytical review indicates conflicting, atypical, or inconclusive results.

Retatrutide Research Overview

What is Retatrutide?

Retatrutide is a synthetic, lipidated peptide engineered to interact with three metabolic hormone receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR), glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR).

Unlike research compounds that primarily activate one metabolic receptor, Retatrutide combines activity at all three receptor systems within a single peptide molecule. This triple-receptor design has made it an important research subject for investigating the coordinated regulation of appetite, glucose metabolism, lipid utilisation, energy expenditure and body weight.

The molecule consists of a modified 39-amino-acid peptide backbone together with structural modifications intended to alter stability and pharmacokinetic behaviour. Published structural descriptions identify a lipid modification involving a C20 fatty diacid, along with non-standard amino-acid substitutions within the peptide sequence.

Understanding Triple-Receptor Agonism in Simple Terms

GIP, GLP-1 and glucagon are naturally occurring signalling hormones involved in how the body responds to food and manages stored and circulating energy.

GLP-1 receptor signalling is involved in appetite regulation, gastric activity, glucose-dependent insulin signalling and nutrient handling.

GIP receptor signalling participates in glucose-dependent insulin secretion, nutrient metabolism and metabolic communication between several tissues.

Glucagon receptor signalling has important roles in hepatic glucose regulation, substrate utilisation and energy metabolism.

Retatrutide allows researchers to investigate what happens when these three signalling pathways are activated together rather than studied individually.

This combined activity is one of the major reasons Retatrutide has become an important model compound for studying multi-receptor approaches to metabolic regulation.

GIP, GLP-1 and Glucagon Receptor Signalling

The three receptors targeted by Retatrutide belong to the G-protein-coupled receptor family and participate in complex signalling networks involved in metabolic homeostasis.

GLP-1 and GIP signalling are closely associated with nutrient-responsive insulin secretion and metabolic signalling following food intake. Glucagon signalling traditionally has been associated with hepatic glucose regulation, although research also examines its effects on lipid metabolism, substrate utilisation and energy expenditure.

Combining these activities provides researchers with a model for studying whether coordinated receptor activation produces biological effects that differ from activation of a single receptor or a dual-receptor combination.

Published receptor studies have confirmed activity at all three receptor systems, supporting Retatrutide's classification as a GIPR/GLP-1R/GCGR triple agonist.

Energy Balance and Body-Weight Research

One of the most extensively investigated areas of Retatrutide research involves energy balance and body-weight regulation.

Researchers are interested in how the combination of appetite-associated incretin signalling and glucagon-receptor activity may influence both sides of the energy-balance equation: energy intake and energy utilisation.

In a randomized 48-week phase 2 human study involving adults with obesity or overweight plus a weight-related condition, Retatrutide produced dose-dependent changes in body weight. At 48 weeks, the highest-dose study group had a mean body-weight change of approximately −24.2%, compared with approximately −2.1% with placebo. These results relate to a controlled clinical study population and should not be interpreted as establishing outcomes for research materials sold outside clinical trials.

The findings have generated continued research into the relative contributions of appetite regulation, nutrient signalling, substrate utilisation and energy expenditure to the observed changes.

Glucose and Lipid Metabolism Research

Retatrutide is also being investigated for its influence on glucose homeostasis and lipid metabolism.

Because GIP and GLP-1 receptors participate in glucose-dependent insulin signalling, while glucagon receptors influence hepatic and whole-body energy metabolism, triple-receptor activation provides a useful research model for examining the interaction between these pathways.

Human clinical research has reported changes in several cardiometabolic measurements alongside changes in body weight, including glucose, insulin and lipid-related measurements. More recent metabolic analyses have also examined changes in biomarkers associated with fatty-acid oxidation, insulin resistance and substrate utilisation.

These findings remain areas of active investigation rather than established properties of laboratory research material.

Molecular Design

Retatrutide is a 39-residue synthetic peptide engineered from a GIP-related peptide backbone.

Its molecular architecture includes several non-standard structural features intended to influence receptor activity and molecular stability.

Reported structural characteristics include:

  • 39 amino-acid residues
  • a single peptide chain
  • GIP-derived peptide architecture
  • aminoisobutyric acid residues at positions 2 and 20
  • an α-methyl-leucine modification at position 13
  • lipid modification associated with Lys17
  • a linker incorporating γ-glutamic-acid/AEEA chemistry
  • a C20 fatty-diacid component
  • an amidated C-terminus

The lipid component contributes to albumin association and prolonged pharmacokinetic behaviour compared with an unmodified peptide backbone.

Human Research

Retatrutide has progressed beyond preclinical investigation and has been evaluated in controlled human clinical research.

Published phase 2 studies have investigated body weight, metabolic parameters, tolerability and dose-response relationships. Larger phase 3 clinical programs have subsequently examined the compound across populations with obesity, overweight and associated metabolic conditions.

As of September 2026, multiple phase 3 studies have been conducted or remain active, while additional studies continue to evaluate longer-term metabolic, cardiovascular and related outcomes.

Human clinical-trial findings apply to the specifically manufactured investigational drug used under controlled research protocols. They do not establish equivalence, safety or efficacy for independently supplied research-grade materials.

Important Evidence Limitations

Although Retatrutide has a growing human clinical evidence base, several important limitations should be recognized.

Clinical findings are generated using specifically manufactured investigational material administered under formal clinical-trial protocols with defined participant selection, dosing, monitoring and quality controls.

Laboratory research materials should therefore not be assumed to be clinically interchangeable with material used in published trials.

HPLC purity alone also does not establish total peptide quantity, identity, sterility, endotoxin status or suitability for biological use. Each analytical measurement addresses a different characteristic of the sample.

Long-term safety, broader population effects and several clinical outcomes remain subjects of ongoing investigation.

Research Status

Retatrutide remains an investigational metabolic research compound.

Phase 3 research programs are evaluating its effects across several obesity- and metabolic-related study populations. Canadian clinical-trial records continue to list Retatrutide in ongoing investigational studies.

Retatrutide is not authorized by Health Canada as an injectable research product for consumer therapeutic use. Health Canada has specifically identified unauthorized Retatrutide products among peptide products marketed online and has stated that “research use only” labelling does not itself exempt a product from applicable regulatory requirements.

For laboratory research only. Not for human or veterinary use.

Retatrutide Product Specifications

Product Identification

Product name: Retatrutide

Development identifier: LY3437943

Compound type: Synthetic lipidated peptide

Research classification: GIPR / GLP-1R / GCGR triple-receptor agonist

Research category: Metabolic signalling and receptor-pharmacology research

CAS number: 2381089-83-2

Peptide length: 39 amino-acid residues

Available nominal strengths: 15 mg / 30 mg / 50 mg

Format: Lyophilized research material supplied in a sealed laboratory vial

Intended classification: Laboratory research reagent

Molecular Structure and Composition

Structural class: Single-chain lipidated synthetic peptide

Peptide backbone: GIP-derived peptide architecture

Representative molecular formula: C₂₂₁H₃₄₂N₄₆O₆₈

Representative molecular weight: Approximately 4,731 Da

Non-standard residues: Aminoisobutyric acid residues at positions 2 and 20 and α-methyl-leucine at position 13

Lipid modification: C20 fatty-diacid modification associated with Lys17 through a linker system

C-terminal structure: Amidated

Disulfide bonds: None

The molecular formula and molecular weight represent the defined modified peptide structure and should be distinguished from values that may be reported for alternative salt, counterion or analytical forms.

Physical Specifications

Physical form: Lyophilized powder

Typical appearance: White to off-white lyophilized material

Presentation: Sealed laboratory vial

Nominal vial content: As indicated on the individual product label and batch documentation

Physical appearance alone does not establish peptide identity, purity or quantity.

Analytical Specifications

Primary purity assessment: High-performance liquid chromatography (HPLC)

Identity assessment: Mass-spectrometric or other identity analysis where specifically performed and reported

Purity reporting: Batch-specific analytical value

Quantity/content determination: Reported independently where quantitative content testing has been performed

Acceptance reporting: Based on the analytical documentation applicable to the individual batch

HPLC purity represents the relative chromatographic purity of the analyzed sample and should not be interpreted independently as confirmation of total peptide quantity or vial content.

Batch-Testing Information

Each production batch should be identified using its individual lot or batch number and linked to the corresponding analytical documentation.

Where performed, batch documentation may include:

  • HPLC chromatographic purity analysis
  • identity assessment
  • mass-spectrometric characterization
  • quantitative content or mass determination
  • analytical laboratory information
  • sample or batch identification
  • date of testing
  • applicable Certificate of Analysis

Only analytical tests actually performed on the applicable batch should be represented as completed.

Sterility, endotoxin, microbial or other pharmaceutical-quality attributes should not be implied unless specifically tested using an appropriate validated analytical method.

Storage Specifications

Recommended storage: 2–8°C

Light exposure: Protect from unnecessary light exposure

Moisture: Maintain material in a sealed, dry environment

Container: Keep vial securely closed until required for laboratory analysis

Stability: Batch-specific stability should not be assumed beyond available analytical or manufacturer documentation

Storage information relates to preservation of laboratory research material and does not constitute preparation or administration instructions.

Intended Use and Restrictions

Retatrutide supplied under this specification is intended exclusively for:

  • laboratory research
  • analytical testing
  • receptor-signalling research
  • peptide-characterization studies
  • biochemical and molecular research
  • qualified scientific investigation

Not for human consumption.

Not for human or veterinary use.

Not intended for diagnosis, treatment, cure or prevention of disease.

Not represented as sterile or suitable for injection unless such characteristics have been independently established by appropriate validated testing.

Documentation Notice

Product specifications describe the general identity and research classification of Retatrutide.

Actual purity, quantity, identity and other analytical characteristics are batch-specific and should be determined from the Certificate of Analysis and associated laboratory documentation for the applicable lot.

Published scientific literature describes Retatrutide as investigated under controlled experimental and clinical conditions. Published research results should not be interpreted as analytical verification of any independently supplied research material.

For laboratory research only. Not for human or veterinary use.

TESTING METHODOLOGY

Each batch undergoes analytical review using validated laboratory procedures. HPLC testing is utilized to assess purity and compare the sample profile against established reference standards. Where additional verification is warranted, LC-MS analysis may be performed to support compound identity confirmation.

OUR ANALYTICAL VERIFICATION PROGRAM

  • Primary Testing: HPLC purity analysis and reference comparison
  • Identity Confirmation: LC-MS performed when indicated*
  • Quality Standards: Batch traceability, analytical documentation, third-party testing and storage procedures

*See LC-MS Confirmation Information for full details.

Every batch supplied by Vanguard Compound Research is assigned a unique batch number and maintained under documented quality-control procedures with supporting analytical documentation available upon request.

SHIPPING & FULFILLMENT

FULFILLMENT INFORMATION
Ships from Canada

All orders ship from within Canada.

Batch Documentation Available

Batch records and analytical documentation may be provided for qualifying products.

Secure Packaging

Products are packaged securely to ensure safe delivery.

Tracking Provided

Tracking information is provided for every shipment.

Temperature-Conscious Handling

Frozen or ambient-safe packaging used as appropriate.

All Vanguard Compound Research orders are shipped directly from within Canada, ensuring efficient delivery, reliable service, and consistent quality-control from fulfillment to arrival.

Canadian Researchers Benefit From:

  • Domestic shipping with no customs delays
  • Batch-specific third-party laboratory testing
  • Full lot number traceability on every product
  • Access to batch-specific Certificates of Analysis (COAs)
  • Dedicated customer support

Canada-Wide Fulfillment:

  • Orders processed Monday through Friday
  • Shipments dispatched throughout Canada
  • Discreet and secure packaging
  • Tracking provided with every shipment

Batch Documentation & Testing

Products are maintained under documented quality-control procedures to help ensure quality, consistency, and transparency.

  • HPLC purity analysis
  • Reference-standard comparison
  • Additional verification procedures (e.g. LC-MS confirmation) may be performed where warranted
  • Lot number traceability

Each product is assigned a unique lot number, allowing researchers to match their item directly to its corresponding Certificate of Analysis (COA).

Analytical Documentation

Supporting analytical documentation may be available for qualifying products, including batch-specific quality records and testing information.

Documentation may include:
  • Batch Number
  • Analytical Results
  • Traceability Records
  • Storage Information

RELATED PRODUCTS